Skip to main content
. 2009 Mar 1;32(3):351–360. doi: 10.1093/sleep/32.3.351

Table 4.

Incidence of Adverse Events Occurring in more than 3% of Subjects

Adverse Event Placebo (n = 223) Ramelteon (n = 228)
Headache 18 (8.1) 18 (7.9)
Upper respiratory tract infection 6 (2.7) 11 (4.8)
Nasopharyngitis 11 (4.9) 10 (4.4)
Urinary tract infection 9 (4.0) 9 (3.9)
Dizziness 5 (2.2) 7 (3.1)
Nausea 8 (3.6) 7 (3.1)

Data are presented as number (%).